薛婧，研究员，博士研究生导师，感染性疾病研究中心主任。曾获中华医学科学技术奖二等奖、教育部科技进步二等奖。获得国家自然科学基金委优秀青年科学基金、中央高校青年教师科研创新支持项目（简称教育部U40项目）、国家重点研发计划青年科学家项目、国家自然科学基金猴痘专项等项目资助。

长期从事艾滋病及突发传染病的感染与免疫机制研究，艾滋病/猴痘非人灵长类动物模型与新药、疫苗等防治策略开发，以及功能性治愈策略探索等研究工作。

1.Ju B#*, Liu C#, Zhang J#, Li Y#, Yang H#, Zhou B#, Huang B#, Ma J, Lu J, Cheng L, Cong Z, Zhu L, Shi T, Sun Y, Li N, Chen T, Wang M, Tang S, Ge X, Zhao J, Tan WJ*, Yan R*, Xue J*, Zhang Z*. Structurally conserved human anti-A35 antibodies protect mice and macaques from mpox virus infection. Cell. 2025 Oct 30;188(22):6253-6265.e14. (IF=42.5)

2.Zhu L#, Liu Q#, Hou Y#, Huang B#, Zhang D, Cong Z, Ma J, Li N, Lu J, Zhang J, Zhang L, Chen T, Wei Q, Liu J, Tan W*, Xue J*. MPXV infection activates cGAS-STING signaling and IFN-I treatment reduces pathogenicity of mpox in CAST/EiJ mice and rhesus macaques. Cell Rep Med. 2025 May 20;6(5):102135. (IF=11.70)

3.Zhu L#, Pan S#, Huang B#, Zhang J#, Yang Z, Cong Z, Ma J, Qiu S, Liu Y, Zhang J, Li N, Lu J, Chen T, Hou Y, Zhang D, Wei Q, Li D*, Tan W*, Zhang Y*, Xue J*. Tiantan vaccinia virus-based vaccine with promising safety provides sustained protection against mpox in non-human primates. Nat Commun. 2025 Aug 5;16(1):7183. (IF=15.70)

4.Zhang D#, Liu J#, Zhu L#, Huang B#, Cong Z, Li N, Zhang J, Chen T, Ma J, Lu J, Hou Y, Yang C, Peng W, Wei Q*, Tan W*, Yang J*, Xue J*. The pathogenicity and multi-organ proteomic profiles of Mpox virus infection in SIVmac239-infected rhesus macaques. Nat Commun. 2025 Aug 17;16(1):7653. (IF=15.70)

5.Chi H#, Zhao SQ#, Liu YP#, Xiong XC#, Zhong X#, Suo XX, Huang XY, Yue C, Zhang JJ, Cong Z, Li N, Du FX, Chen T, Ma JR, Wang L, Ying B, Deng YQ, Yin JY*, Wang X*, Xue J*, Qin CF*. Efficacy and safety of an mRNA encoding neutralizing antibody against SARS-CoV-2 in non-human primates. Sci Bull (Beijing). 2025 Sep 30;70(18):2948-2952. (IF=18.8)

6.Sun Y#, Yang C#, Liu P#, Cong Z, Luo J, Tong L, Zhang J, Lu J, Jia Z, Zhu L, Lu Q, Chen T, Wei Q, Li D*, Hou R*, Xue J*. Novel insights into immune checkpoints in HIV/SHIV infection: from SHIV_SF162P3-infected elite controllers to therapeutic strategy. J Virol. 2025 Aug 19;99(8):e0078525. (IF=3.80)

7.Xue J*#, Zhu Y#, Yang C#, Liu X#, Hou R#, Wang W#, Chong H#, Cong Z, Zhang J, Tong L, Lu J, Liu P, Chen T, Li N, Wei Q, He Y*. An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques. Cell Rep. 2025 Sep 4;44(9):116228. (IF=6.90)

8.Zhao R#, Wu L#, Zhang Y#, Ma J#, Liu D, Zheng Y, Kong T, Ma R, Gao Z, Chai Y, Liu Y, Tian Y, Xia Y, Hou Y, Lu J, Cong Z, Huang B, Tan W, Xue J*, Gao GF, Wang Q*. Anti-M1R/B6R antibody characterization and bispecific design for enhanced orthopoxvirus protection. EMBO Mol Med. 2025 Sep 8. (IF=8.30)

9.Cong Z(#), Wei Y(#), Chong H(#), Zhang D, Tong L, Zhang J, Zhu Y, Gao Z, Jin H, Lu J, Lu Q, Chen T, Wei Q, Ma G, He Y*, Gong F*, Xue J*. Prolonged release and antiviral efficacy of HIV fusion inhibitor LP-98-loaded microspheres in rhesus macaques. J Control Release. 2024 Oct 23;376:530-541. (IF=10.5)

10.Xue J#*, Chong H#, Zhu Y# , Zhang J, Tong L, Lu J, Chen T, Cong Z, Wei Q, He Y*. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell. 2022 Jan 6;185(1):131-144.e18. (IF=66.85)